- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03607435
A Clinical Study to Collect Calibration & Performance Data of the KBS Systems 1.0 Non-Invasive Glucose Monitoring Device
The purpose of this study is to calibrate the performance of the KBS-1 non-invasive glucose monitoring device with diabetic people when compared to that of the standard method currently used in the clinical setting for prescription point-of-care (POC) blood glucose monitoring. The secondary purpose of this study is to calibrate the performance of the RBA-1 minimally invasive bodily fluid analyte analyzer device when compared to the results from a prescription POC blood glucose monitoring device and/or standard hospital laboratory blood test.
The objective of this study is to collect non-invasive in vivo, and potentially in vitro, spectral measurements of interstitial fluid glucose from underneath the skin of the palm of the hand (Test Article #01), and potentially the blood, respectively, from diabetic adult hospital staff participants, and to collect in vitro spectral measurements of venous blood tested from adult hospital patients with or without diabetes (Test Article #02) and compare them to POC blood glucose monitor values and analyte measurements conducted by a hospital laboratory (Control Article #01 procedure), respectively.
The comparison of the results obtained from the different analytical methods will be used to calibrate and refine the glucose, and other, analyte level calculation algorithms of the Test Article systems.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33613
- Recruiting
- Florida Hospital Tampa
-
Contact:
- Juliet Bala, CCRC
- Phone Number: 813-610-8110
- Email: juliet.bala@ahss.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Ideally, all enrolled participants will represent an ethnically diverse population with as close to an even ratio of males to females as possible.
1) Age ≥ 21 years. 2) Willingness and ability to provide informed consent.
Additional inclusion criteria specific to KBS-1 (Test Article #01) testing:
1) Diabetic hospital staff
Additional inclusion criteria specific to RBA-1 (Test Article #02) testing:
- Hospital patients with a physician prescribed hospital laboratory blood test.
Diabetic hospital staff
Exclusion Criteria:
The following exclusion criteria apply to all prospective study participants.
- A member of a vulnerable population (i.e. children, pregnant women, prisoners, etc.)
- People with clotting factor disorders and/or currently taking anticoagulation medication.
- Has any other medical condition that, in the opinion of the Investigator, would interfere with the person's participation in this study (i.e. double arm amputee).
Additional exclusion criteria specific to KBS-1 (Test Article #01) testing:
- Any skin abnormalities or tattoos located on the palm(s) of the hand(s). The left palm is preferred for this study; however, the right palm can be used if the left palm is excluded.
- Parkinson's disease, dyskinesia, tremors, or similar that may make it challenging for said person to hold their hand on the device in a still and stable manner.
Additional inclusion criteria specific to RBA-1 (Test Article #02) testing:
- Patient is in isolation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Test Article Scanning
Spectroscopy for Analyte Quantification
|
Diabetic hospital staff participants subjected to the KBS-1 device (Test Article #01) will have a finger on their left hand pricked with a lancet and their blood glucose level read by a POC glucose monitor (Control Article #02).
Next, they will have their interstitial fluid glucose level spectroscopically scanned from the palm of their left hand using the KBS-1 device, and blood (approximately 40µl), collected from their finger prick site, will be spectroscopically scanned using the RBA-1 device (Test Article #02).
Hospital patients subjected to the RBA-1 device, who must already be prescribed a hospital lab blood test by their physician, will have approximately 40µl of their blood, collected from the venipuncture site, spectroscopically scanned using the RBA-1 device (Test Article #02).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Calibration of the KBS-1 Test Article using the POC Control data for comparison.
Time Frame: The test article and control article procedure together will take approximately 10 - 15 minutes of the research participant's time.
|
The data gathered by the Test Article procedures will be compared to the data gathered by the POC Control Article procedure in order to accomplish:
|
The test article and control article procedure together will take approximately 10 - 15 minutes of the research participant's time.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Research Subject Assessment
Time Frame: The assessment will take place immediately at the conclusion of the KBS-1 and POC glucose monitoring procedure and will take approximately 1 minute of the research participant's time.
|
The research subjects will be questioned on the presence (Y or N) of any pain or discomfort related to the KBS-1 test article procedure, as well as ease of use and acceptability (1-5 rating scale, 1=bad, 5=excellent).
|
The assessment will take place immediately at the conclusion of the KBS-1 and POC glucose monitoring procedure and will take approximately 1 minute of the research participant's time.
|
Calibration of the RBA-1 Test Article using the hospital lab test Control data and POC blood glucose monitor Control data for comparison.
Time Frame: The test and control article procedure together will take approximately 10 minutes of a research participant's time.
|
The data gathered by the Test Article procedure will be compared to the data gathered by the Control Article procedure(s) in order to accomplish:
|
The test and control article procedure together will take approximately 10 minutes of a research participant's time.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Patrick J Stocker, PhD, Kaligia Biosciences, LLC
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- KBS002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
Clinical Trials on Spectroscopy for Analyte Quantification
-
Karolinska InstitutetMbarara University of Science and Technology; Science for Life Laboratory; Epicentre... and other collaboratorsCompleted
-
Suhu LiuRecruitingAcute Myeloid LeukemiaUnited States
-
Ottawa Hospital Research InstituteCompletedCritical Illness | Pharmacokinetics | Kidney InjuryCanada
-
Brigham and Women's HospitalBoston University; U.S. Army Medical Research and Development CommandCompleted
-
Shanghai Jiao Tong University School of MedicineShanghai Photonic View Technology Co., Ltd.Not yet recruitingType 2 Diabetes | Medical DeviceChina
-
Shanghai Jiao Tong University School of MedicineShanghai Photonic View Technology Co., Ltd.Not yet recruitingDiabetes Mellitus | Medical Device
-
British Columbia Cancer AgencyM.D. Anderson Cancer Center; University of Texas at AustinCompleted
-
Thames Valley UniversityWembley Health Care centre, NHS, UK.; Monks Park Primary care centre, NHS UK.; Willesden Health centre, NHS, UK...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Pauls Stradins Clinical University HospitalRecruiting
-
OrganogenesisTerminatedChronic Pressure UlcersUnited States